Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreas

Clinical Journal of Oncology Nursing

Volumn 12, Issue 4, 2008, Pages 599-605

  Iott, Matthew J ^a   Corsini, Michele M ^a   Miller, Robert C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CAUSE OF DEATH; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; HUMAN; METHODOLOGY; MORTALITY; ONCOLOGY NURSING; PANCREAS RESECTION; PANCREAS TUMOR; PATHOLOGY; PATIENT SELECTION; POSTOPERATIVE CARE; PRACTICE GUIDELINE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STANDARD; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CAUSE OF DEATH; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; ONCOLOGIC NURSING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PATIENT SELECTION; POSTOPERATIVE CARE; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 55249090895     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/08.CJON.599-605     Document Type: Article

References (18)

1. Bergenfeldt, M., & Albertsson, M. (2006). Current state of adjuvant therapy in resected pancreatic adenocarcinoma. Acta Onco-logica, 45(2), 124-135.
2. Choti, M.A. (2004). Adjuvant therapy for pancreatic cancer: The debate continues. New England Journal of Medicine, 350(12), 1249-1251.
3. Chu, Q.D., Khushalani, N., Javle, M.M., Douglass, H.O., Jr., & Gibbs, J.F. (2003). Should adjuvant therapy remain the standard of care for patients with resected adenocarcinoma of the pancreas? Annals of Surgical Oncology, 10(5), 539-545.
4. Corsini, M.M., Miller, R.C., Haddock, M.G., Donohue, J.H., Farnell, M.B., Nagorney, D.M., et al. (2007). Adjuvant radiation and chemotherapy for pancreatic adenocarcinoma:The Mayo Clinic.
5. DiMagno, E.P., Reber, H.A., & Tempero, M.A. (1999). AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology, 117(6), 1464-1484.
6. Garofalo, M.C., Regine, W.F., & Tan, M.T. (2006). On statistical reanal-ysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Annals of Surgery, 244(2), 332-333.
7. Gastrointestinal Tumor Study Group. (1987). Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. CA: A Cancer Journal for Clinicians, 59(12), 2006-2010.
8. Halls, B.S., & Ward-Smith, P. (2007). Identifying early symptoms of pancreatic cancer. Clinical Journal of Oncology Nursing, 11 (2), 245-248.
9. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., et al. (2006). Cancer statistics, 2006. CA: A Cancer Journal for Clinicians, 56(2), 106-130.
10. Kalser, M.H., & Ellenberg, S.S. (1985). Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Archives of Surgery, 120(8), 899-903.
11. Klinkenbijl, J.H., Jeekel, J., Sahmoud, T., van Pel, R., Couvreur, M.L., Veenhof, C.H., et al. (1999). Adjuvant radiotherapy and 5-fuorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Annals of Surgery, 230 (6), 776-782.
12. TM: Pancreatic adenocarcinoma [v.1.2008]. Retrieved July 16, 2008, from http://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf
13. Neoptolemos, J.P., Stocken, D.D., Friess, H., Bassi, C., Dunn, J.A., Hickey, H., et al. (2004). A randomized trial of chemoradiothera-py and chemotherapy after resection of pancreatic cancer. New England Journal of Medicine, 350(12), 1200-1210.
14. Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., et al. (2007). Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA, 297(3), 267-277.
15. Regine, W.F., & Abrams, R.A. (2006). Adjuvant therapy for pancreatic cancer: Current status, future directions. Seminars in Oncology, 33(6 Suppl., 11), S10-S13.
16. Regine, W.F., Winter, K.W., Abrams, R., Safran, H., Hoffman, J.P., Konski, A., et al. (2006). RTOG 9704: A phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma [Abstract]. Journal of Clinical Oncology, 24(Supp. 1), 4007. Retrieved February 2, 2007, from http://www.asco.org/portal/site/ASCO/menuitem.34 d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a70 10VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&index=y&abstractID=30809
17. Stocken, D.D., Buchler, M.W., Der venis, C., Bassi, C., Jeekel, H., Klin-kenbijl, J.H., et al. (2005). Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. British Journal of Cancer, 92(8), 1372-1381.
18. Swartz, M.J., Abrams, R.A., Winter, J., Cameron, J., Laheru, D., Yeo, C., et al. (2006). Adjuvant chemoradiation for adenocarcinoma of the pancreas: The Johns Hopkins experience [Abstract]. International Journal of Radiation Oncology Biology Physics, 66(3, Suppl., 1), S82.